{
    "ticker": "XB",
    "name": "Xenon Biopharma Inc.",
    "description": "Xenon Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare neurological disorders and other serious medical conditions. Founded in 1996, Xenon is dedicated to advancing the understanding of genetic diseases and translating that knowledge into effective treatments. The company\u2019s proprietary drug development platform leverages human genetics to identify and validate novel drug targets, particularly in the field of neurology. Xenon's lead product candidate, XEN1101, is a novel sodium channel blocker currently in clinical trials for the treatment of epilepsy. The company's pipeline also includes therapies aimed at addressing conditions such as pain and movement disorders. With a strong commitment to scientific excellence and patient-centric solutions, Xenon Biopharma aims to improve the lives of patients suffering from underserved medical conditions. The company fosters collaborations with academic institutions and other industry leaders to accelerate drug discovery and development. Xenon is headquartered in Vancouver, Canada, and is committed to building a robust portfolio of therapies that address significant unmet medical needs.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Vancouver, Canada",
    "founded": "1996",
    "website": "https://www.xenon-pharma.com",
    "ceo": "Simon Pimstone",
    "social_media": {
        "twitter": "https://twitter.com/XenonPharma",
        "linkedin": "https://www.linkedin.com/company/xenon-pharmaceuticals/"
    },
    "investor_relations": "https://investors.xenon-pharma.com",
    "key_executives": [
        {
            "name": "Simon Pimstone",
            "position": "CEO"
        },
        {
            "name": "Michael S. P. O'Neill",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "XEN1101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Xenon Biopharma Inc. | Innovative Therapies for Rare Disorders",
        "meta_description": "Xenon Biopharma Inc. is dedicated to developing therapies for rare neurological disorders. Learn about our innovative pipeline and commitment to patient care.",
        "keywords": [
            "Xenon Biopharma",
            "Neurological Disorders",
            "Biopharmaceuticals",
            "XEN1101",
            "Rare Diseases",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What is Xenon Biopharma known for?",
            "answer": "Xenon Biopharma is known for developing innovative therapies for rare neurological disorders."
        },
        {
            "question": "Who is the CEO of Xenon Biopharma?",
            "answer": "Simon Pimstone is the CEO of Xenon Biopharma Inc."
        },
        {
            "question": "Where is Xenon Biopharma headquartered?",
            "answer": "Xenon Biopharma is headquartered in Vancouver, Canada."
        },
        {
            "question": "What are Xenon Biopharma's main products?",
            "answer": "Xenon Biopharma's main product candidate is XEN1101, aimed at treating epilepsy."
        },
        {
            "question": "When was Xenon Biopharma founded?",
            "answer": "Xenon Biopharma was founded in 1996."
        }
    ],
    "competitors": [
        "SAGE",
        "VRTX",
        "ALNY"
    ],
    "related_stocks": [
        "AAPL",
        "AMGN",
        "MRK",
        "PFE"
    ]
}